NCT04699747View on ClinicalTrials.gov

Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Multiple Sclerosis
Interventions
DRUG

F-18 3F4AP

Subjects will be injected once per imaging session (a maximum of 2 imaging sessions) with up to 10 mCi (±20%) of 18-F 3F4AP as a rapid intravenous bolus (within 1 min).

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER